The prostate metastasis suppressor gene NDRG1 differentially regulates cell motility and invasion

Anup Sharma, Janet Mendonca, James Ying, Hea Soo Kim, James E. Verdone, Jelani Zarif, Michael A Carducci, Hans Hammers, Kenneth Pienta, Sushant Kachhap

Research output: Contribution to journalArticle

Abstract

Experimental and clinical evidence suggests that N-myc downregulated gene 1 (NDRG1) functions as a suppressor of prostate cancer metastasis. Elucidating pathways that drive survival and invasiveness of NDRG1-deficient prostate cancer cells can help in designing therapeutics to target metastatic prostate cancer cells. However, the molecular mechanisms that lead NDRG1-deficient prostate cancer cells to increased invasiveness remain largely unknown. In this study, we demonstrate that NDRG1-deficient prostate tumors have decreased integrin expression and reduced cell adhesion and motility. Our data indicate that loss of NDRG1 differentially affects Rho GTPases. Specifically, there is a downregulation of active RhoA and Rac1 GTPases with a concomitant upregulation of active Cdc42 in NDRG1-deficient cells. Live cell imaging using a fluorescent sensor that binds to polymerized actin revealed that NDRG1-deficient cells have restricted actin dynamics, thereby affecting cell migration. These cellular and molecular characteristics are in sharp contrast to what is expected after loss of a metastasis suppressor. We further demonstrate that NDRG1-deficient cells have increased resistance to anoikis and increased invasiveness which is independent of its elevated Cdc42 activity. Furthermore, NDRG1 regulates expression and glycosylation of EMMPRIN, a master regulator of matrix metalloproteases. NDRG1 deficiency leads to an increase in EMMPRIN expression with a concomitant increase in matrix metalloproteases and thus invadopodial activity. Using a three-dimensional invasion assay and an in vivo metastasis assay for human prostate xenografts, we demonstrate that NDRG1-deficient prostate cancer cells exhibit a collective invasion phenotype and are highly invasive. Thus, our findings provide novel insights suggesting that loss of NDRG1 leads to a decrease in actinmediated cellular motility but an increase in cellular invasion, resulting in increased tumor dissemination which positively impacts metastatic outcome.

Original languageEnglish (US)
Pages (from-to)655-669
Number of pages15
JournalMolecular Oncology
Volume11
Issue number6
DOIs
StatePublished - 2017

Fingerprint

myc Genes
Tumor Suppressor Genes
Cell Movement
Prostate
Down-Regulation
Prostatic Neoplasms
Metalloproteases
Neoplasm Metastasis
Actins
Anoikis
rho GTP-Binding Proteins
GTP Phosphohydrolases
Glycosylation
Heterografts
Cell Adhesion
Integrins
Neoplasms
Up-Regulation

Keywords

  • Actin cytoskeleton
  • Matrix metalloproteases
  • Metastasis
  • Prostate cancer

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Cancer Research

Cite this

The prostate metastasis suppressor gene NDRG1 differentially regulates cell motility and invasion. / Sharma, Anup; Mendonca, Janet; Ying, James; Kim, Hea Soo; Verdone, James E.; Zarif, Jelani; Carducci, Michael A; Hammers, Hans; Pienta, Kenneth; Kachhap, Sushant.

In: Molecular Oncology, Vol. 11, No. 6, 2017, p. 655-669.

Research output: Contribution to journalArticle

Sharma, Anup ; Mendonca, Janet ; Ying, James ; Kim, Hea Soo ; Verdone, James E. ; Zarif, Jelani ; Carducci, Michael A ; Hammers, Hans ; Pienta, Kenneth ; Kachhap, Sushant. / The prostate metastasis suppressor gene NDRG1 differentially regulates cell motility and invasion. In: Molecular Oncology. 2017 ; Vol. 11, No. 6. pp. 655-669.
@article{c65ddbe4230248fa816dd97fc79026d5,
title = "The prostate metastasis suppressor gene NDRG1 differentially regulates cell motility and invasion",
abstract = "Experimental and clinical evidence suggests that N-myc downregulated gene 1 (NDRG1) functions as a suppressor of prostate cancer metastasis. Elucidating pathways that drive survival and invasiveness of NDRG1-deficient prostate cancer cells can help in designing therapeutics to target metastatic prostate cancer cells. However, the molecular mechanisms that lead NDRG1-deficient prostate cancer cells to increased invasiveness remain largely unknown. In this study, we demonstrate that NDRG1-deficient prostate tumors have decreased integrin expression and reduced cell adhesion and motility. Our data indicate that loss of NDRG1 differentially affects Rho GTPases. Specifically, there is a downregulation of active RhoA and Rac1 GTPases with a concomitant upregulation of active Cdc42 in NDRG1-deficient cells. Live cell imaging using a fluorescent sensor that binds to polymerized actin revealed that NDRG1-deficient cells have restricted actin dynamics, thereby affecting cell migration. These cellular and molecular characteristics are in sharp contrast to what is expected after loss of a metastasis suppressor. We further demonstrate that NDRG1-deficient cells have increased resistance to anoikis and increased invasiveness which is independent of its elevated Cdc42 activity. Furthermore, NDRG1 regulates expression and glycosylation of EMMPRIN, a master regulator of matrix metalloproteases. NDRG1 deficiency leads to an increase in EMMPRIN expression with a concomitant increase in matrix metalloproteases and thus invadopodial activity. Using a three-dimensional invasion assay and an in vivo metastasis assay for human prostate xenografts, we demonstrate that NDRG1-deficient prostate cancer cells exhibit a collective invasion phenotype and are highly invasive. Thus, our findings provide novel insights suggesting that loss of NDRG1 leads to a decrease in actinmediated cellular motility but an increase in cellular invasion, resulting in increased tumor dissemination which positively impacts metastatic outcome.",
keywords = "Actin cytoskeleton, Matrix metalloproteases, Metastasis, Prostate cancer",
author = "Anup Sharma and Janet Mendonca and James Ying and Kim, {Hea Soo} and Verdone, {James E.} and Jelani Zarif and Carducci, {Michael A} and Hans Hammers and Kenneth Pienta and Sushant Kachhap",
year = "2017",
doi = "10.1002/1878-0261.12059",
language = "English (US)",
volume = "11",
pages = "655--669",
journal = "Molecular Oncology",
issn = "1574-7891",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - The prostate metastasis suppressor gene NDRG1 differentially regulates cell motility and invasion

AU - Sharma, Anup

AU - Mendonca, Janet

AU - Ying, James

AU - Kim, Hea Soo

AU - Verdone, James E.

AU - Zarif, Jelani

AU - Carducci, Michael A

AU - Hammers, Hans

AU - Pienta, Kenneth

AU - Kachhap, Sushant

PY - 2017

Y1 - 2017

N2 - Experimental and clinical evidence suggests that N-myc downregulated gene 1 (NDRG1) functions as a suppressor of prostate cancer metastasis. Elucidating pathways that drive survival and invasiveness of NDRG1-deficient prostate cancer cells can help in designing therapeutics to target metastatic prostate cancer cells. However, the molecular mechanisms that lead NDRG1-deficient prostate cancer cells to increased invasiveness remain largely unknown. In this study, we demonstrate that NDRG1-deficient prostate tumors have decreased integrin expression and reduced cell adhesion and motility. Our data indicate that loss of NDRG1 differentially affects Rho GTPases. Specifically, there is a downregulation of active RhoA and Rac1 GTPases with a concomitant upregulation of active Cdc42 in NDRG1-deficient cells. Live cell imaging using a fluorescent sensor that binds to polymerized actin revealed that NDRG1-deficient cells have restricted actin dynamics, thereby affecting cell migration. These cellular and molecular characteristics are in sharp contrast to what is expected after loss of a metastasis suppressor. We further demonstrate that NDRG1-deficient cells have increased resistance to anoikis and increased invasiveness which is independent of its elevated Cdc42 activity. Furthermore, NDRG1 regulates expression and glycosylation of EMMPRIN, a master regulator of matrix metalloproteases. NDRG1 deficiency leads to an increase in EMMPRIN expression with a concomitant increase in matrix metalloproteases and thus invadopodial activity. Using a three-dimensional invasion assay and an in vivo metastasis assay for human prostate xenografts, we demonstrate that NDRG1-deficient prostate cancer cells exhibit a collective invasion phenotype and are highly invasive. Thus, our findings provide novel insights suggesting that loss of NDRG1 leads to a decrease in actinmediated cellular motility but an increase in cellular invasion, resulting in increased tumor dissemination which positively impacts metastatic outcome.

AB - Experimental and clinical evidence suggests that N-myc downregulated gene 1 (NDRG1) functions as a suppressor of prostate cancer metastasis. Elucidating pathways that drive survival and invasiveness of NDRG1-deficient prostate cancer cells can help in designing therapeutics to target metastatic prostate cancer cells. However, the molecular mechanisms that lead NDRG1-deficient prostate cancer cells to increased invasiveness remain largely unknown. In this study, we demonstrate that NDRG1-deficient prostate tumors have decreased integrin expression and reduced cell adhesion and motility. Our data indicate that loss of NDRG1 differentially affects Rho GTPases. Specifically, there is a downregulation of active RhoA and Rac1 GTPases with a concomitant upregulation of active Cdc42 in NDRG1-deficient cells. Live cell imaging using a fluorescent sensor that binds to polymerized actin revealed that NDRG1-deficient cells have restricted actin dynamics, thereby affecting cell migration. These cellular and molecular characteristics are in sharp contrast to what is expected after loss of a metastasis suppressor. We further demonstrate that NDRG1-deficient cells have increased resistance to anoikis and increased invasiveness which is independent of its elevated Cdc42 activity. Furthermore, NDRG1 regulates expression and glycosylation of EMMPRIN, a master regulator of matrix metalloproteases. NDRG1 deficiency leads to an increase in EMMPRIN expression with a concomitant increase in matrix metalloproteases and thus invadopodial activity. Using a three-dimensional invasion assay and an in vivo metastasis assay for human prostate xenografts, we demonstrate that NDRG1-deficient prostate cancer cells exhibit a collective invasion phenotype and are highly invasive. Thus, our findings provide novel insights suggesting that loss of NDRG1 leads to a decrease in actinmediated cellular motility but an increase in cellular invasion, resulting in increased tumor dissemination which positively impacts metastatic outcome.

KW - Actin cytoskeleton

KW - Matrix metalloproteases

KW - Metastasis

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85025666347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85025666347&partnerID=8YFLogxK

U2 - 10.1002/1878-0261.12059

DO - 10.1002/1878-0261.12059

M3 - Article

C2 - 28371345

AN - SCOPUS:85025666347

VL - 11

SP - 655

EP - 669

JO - Molecular Oncology

JF - Molecular Oncology

SN - 1574-7891

IS - 6

ER -